Abstract: A beverage dispenser includes a body having a bore with an inlet, an outlet and a valve seat therebetween. A valve stem has a seal to selectively engage the valve seat to open and close the bore to a flow of beverage between the inlet and outlet. A serving lever is pivotally connected to the body and selectively coupled and decoupled to the valve stem by a clutch which is operated by a solenoid. Operating the serving lever may move the seal away from the valve seat only when clutch couples the serving lever to the valve stem. A control circuit operates the solenoid to cause the clutch to decouple the serving lever from the valve stem when the beverage has been dispensed continuously for greater than a defined period of time.

Abstract: A switch, mounted on a standard beverage tap, provides an electrical signal indicating when beverage is being dispensed into a serving container. The electrical signal is applied to a monitor which measures the period of time that the beverage flows from the tap. As beverage dispensing occurs, a series of steps are taken which determine from the time measurements whether the dispensing is proceeding into one container, is complete, is part of a continuous pour into several containers or has been completed with a subsequent single container pouring operation occurring. That determination is based on whether the period of time is within a range indicative of dispensing the beverage into a single serving container. When that determination is made a serving container count is incremented. The monitor also uses the measured time period to detect when the tap is opened for longer than the typical time required to fill a single beverage container.

Abstract: The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

Abstract: Substituted azetidinones are herein disclosed for use in the treatment of various elastase-mediated diseases.

Abstract: A particulate obscurant disseminator couples the shaft power of the host vehicle through a clutch and fluid coupling to a high ratio gear box whose output shaft drives a compressor of an automative-type turbocharger whose air output is fed to the input of a venturi type ejector where additional air flow is induced and mixed with pariculate from a bin supply to form an obscurant cloud.